What Is ADT for Prostate Cancer Treatment?

Androgen deprivation therapy, universally called ADT, is a treatment for prostate cancer that works by drastically lowering or blocking the male hormones (androgens, chiefly testosterone) that fuel prostate cancer growth. It has been the backbone of advanced prostate cancer treatment since the 1940s, when researchers first showed that removing the testes caused tumors to shrink. Today ADT takes several forms, from monthly injections to oral pills to surgery, and it is used across nearly every stage of the disease. The treatment is effective but comes with a wide range of side effects that deserve serious attention.

Why Testosterone Matters in Prostate Cancer

Prostate cancer cells depend on androgens to grow and multiply. Testosterone and its more potent derivative, dihydrotestosterone, bind to androgen receptors on prostate cancer cells and switch on genes that drive tumor growth. This dependency is what makes ADT so powerful: cut the fuel supply and the cancer slows down, shrinks, or stalls. Androgens play a major role in promoting both the development and progression of prostate cancer, and blocking that androgen signal has remained the cornerstone of treatment for advanced disease for more than 80 years.¹

The concept dates back to 1941, when Charles Huggins and Clarence Hodges reported that bilateral orchiectomy (surgical removal of both testes) in men with advanced prostate cancer caused tumor markers to plummet, confirming that the disease was testosterone-dependent.² Huggins later received a Nobel Prize for this discovery. The therapeutic principle has not fundamentally changed since then, but the tools available have expanded dramatically.

Forms of ADT

There are several ways to deprive prostate cancer of testosterone. The choice depends on the stage of disease, your overall health, personal preferences, and sometimes cost.

Surgical Castration

Bilateral orchiectomy remains the fastest and most definitive way to drop testosterone to very low levels. It works within hours, costs less over a lifetime than injectable drugs, and avoids the need for ongoing medication. A large registry study found that surgical castration and medical castration achieved similar cancer outcomes: both suppressed testosterone below the castrate threshold in over 95% of men, and there was no meaningful difference in overall survival or time to castration-resistant disease.³ Despite its effectiveness, most men today prefer drug-based options because orchiectomy is permanent and carries a psychological burden.

GnRH Agonists and Antagonists

The most common form of ADT uses injectable drugs that act on the brain’s hormonal control center. GnRH agonists (such as leuprolide and goserelin) initially cause a brief surge in testosterone before the body’s feedback system shuts production down. GnRH antagonists (such as degarelix and the newer oral drug relugolix) skip that surge and suppress testosterone more immediately. Both classes lower testosterone to castrate levels and are considered the mainstay of advanced prostate cancer treatment.⁴

That initial testosterone surge with agonists, sometimes called a “flare,” matters. A pooled analysis of clinical trials has raised the possibility that GnRH agonists carry a somewhat higher cardiovascular risk compared to the antagonist degarelix, potentially because agonists cause early surges in follicle-stimulating hormone that may affect heart health.⁴ A separate study of over 3,200 men found that those who had orchiectomy rather than GnRH agonists had lower risks of fractures, peripheral artery disease, and cardiac complications.⁵ This does not mean agonists are dangerous, but it has pushed many oncologists toward antagonists for men who already have heart disease.

Antiandrogens and Newer Agents

Traditional antiandrogens (like bicalutamide) block testosterone from binding to the androgen receptor. They are often used alongside GnRH drugs to achieve what is called combined androgen blockade. Newer agents go further. Enzalutamide is a second-generation antiandrogen that blocks the receptor more potently. Abiraterone inhibits an enzyme needed to produce testosterone precursors not just in the testes but also in the adrenal glands and within the tumor itself. These drugs were originally developed for castration-resistant disease but are now used much earlier.

How ADT Is Used in Practice

ADT is not a one-size-fits-all treatment. It might be used alone, alongside radiation, before or after surgery, for a few months, or indefinitely. The strategy depends on how advanced the cancer is and the risk category it falls into.

Alongside Radiation Therapy

For men receiving radiation for localized prostate cancer, ADT is frequently added to improve outcomes. A large meta-analysis found that adding ADT to radiation significantly improved metastasis-free survival, and that extending the ADT given after radiation (adjuvant ADT) further improved results.⁶ The benefits held regardless of the radiation dose, the patient’s age, or the risk group. However, extending ADT given before radiation did not add the same benefit, suggesting the timing and sequencing of ADT relative to radiation matter.

How Long ADT Should Last

Duration is one of the trickiest decisions. A recent meta-analysis looking at ADT duration alongside radiation found that longer ADT improved cancer-specific survival in a diminishing-returns pattern, with most of the benefit achieved by nine to twelve months depending on the endpoint. Meanwhile, the risk of dying from causes other than prostate cancer increased with longer ADT use in a near-linear fashion.⁷ That trade-off means the ideal duration varies: men with one intermediate-risk factor may not benefit from ADT at all alongside radiation, those with multiple intermediate-risk features may do best with about six months, and high-risk disease may warrant twelve months or longer.⁷

Intermittent Versus Continuous ADT

Given the side effects, researchers have tested whether cycling ADT on and off (intermittent therapy) could spare men some of the burden without sacrificing cancer control. A systematic review of eight trials including over 5,300 patients found no meaningful difference in overall survival, cancer-specific survival, or progression-free survival between intermittent and continuous approaches.⁸ A large randomized trial similarly found comparable survival, with intermittent therapy showing better erectile function and mental health early on, although that advantage faded after the first few months.⁹ Most trials did note at least some improvement in physical and sexual functioning with the intermittent approach, which is why it remains a reasonable option in selected patients, particularly those whose PSA drops well on treatment.

Combination and Triplet Therapies for Metastatic Disease

For men with metastatic hormone-sensitive prostate cancer, ADT alone is no longer the standard. Doublet therapy, which combines ADT with either a newer hormonal agent (like abiraterone or enzalutamide) or the chemotherapy drug docetaxel, has become the baseline treatment. More recently, triplet therapy combining ADT with both a newer hormonal agent and docetaxel has shown impressive results in clinical trials.¹⁰ The field has moved quickly on this front. A man diagnosed with metastatic prostate cancer today is likely to receive at least two drugs from the start rather than escalating treatments one at a time.

Side Effects on Body Composition and Heart Health

Testosterone does far more than drive prostate cancer. It maintains muscle mass, keeps body fat in check, supports bone density, and influences cardiovascular health. Stripping it away triggers a cascade of changes throughout the body. Fat gain and lean-mass loss are among the most consistent side effects of ADT.¹¹

These changes happen fast. One study tracking men from the start of ADT found that within months, whole-body fat increased, thigh muscle shrank, leg strength dropped, cardiovascular fitness declined, daily step count fell, and self-reported quality of life worsened.¹² Fasting insulin also rose, which is an early sign of metabolic trouble. ADT has been shown to promote a cluster of metabolic risk factors, including insulin resistance, unfavorable cholesterol shifts, and higher blood pressure, that together raise the risk for heart disease and type 2 diabetes.¹³

The body composition changes are not just cosmetic. Research has found that the degree of muscle loss and fat gain after starting ADT independently predicts the risk of serious cardiovascular events. In one study, men who lost roughly 5% or more of their muscle index and gained about 8% or more in subcutaneous fat had dramatically higher rates of heart attacks, strokes, and related events.¹⁴ This underscores why managing side effects is not optional but part of treatment.

Bone Loss and Fracture Risk

Testosterone helps maintain bone density, and ADT leads to accelerated bone thinning. The resulting loss of bone-mineral density raises fracture risk, and this effect accumulates the longer treatment continues.¹⁵ Many newer prostate cancer agents that have extended survival also affect bone health, compounding the problem.¹⁶

Bone-protecting drugs can help. Zoledronic acid (an intravenous bisphosphonate) and denosumab (an injectable antibody) have both been approved to prevent ADT-related bone loss. Your oncology team should assess bone density at or near the start of ADT and consider preventive treatment, especially if you have additional risk factors like age, smoking, low body weight, or a family history of osteoporosis.

Sexual Function, Mood, and Cognition

Sexual side effects are almost universal on ADT. Desire typically disappears within the first few months, and the sustained absence of testosterone can cause lasting damage to erectile tissue. Even after ADT is stopped, erections do not fully recover in about half of men.¹⁷ Intermittent ADT allows some recovery during off-treatment periods, but testosterone itself typically takes nine to twelve months off therapy to rebound, and recovery of sexual function remains incomplete for many.¹⁸ A prospective study found that by three months on ADT, only about 13% of men were sexually active and only 10% reported moderate to high libido, while half felt less masculine. During the off phase, roughly half of previously active men resumed sexual activity and those who did reported erectile function returning to baseline.¹⁸

Beyond sex, ADT is associated with cognitive changes and mood disturbances. Some studies have linked long-term ADT use to diminished cognitive function, mood swings, depression, lower quality of life, and a possible association with dementia.¹⁹ The evidence on dementia and Alzheimer’s disease risk specifically remains mixed, with some large studies finding an association and others not. What is clearer is that many men on ADT experience brain fog, difficulty concentrating, and emotional changes that affect daily life. Discussing these risks before starting treatment allows men to prepare, and staying mentally and physically active may help.²⁰

Testosterone Recovery After ADT Stops

For men who receive ADT for a defined period rather than lifelong, the question of whether testosterone bounces back matters a great deal. The answer is not reassuring for everyone. In one study, a quarter of men never recovered even to the basic castrate threshold, and a striking 81% never returned to normal testosterone levels.²¹ The two strongest predictors of recovery were how long ADT lasted and how old you were when it stopped. Younger men on shorter courses had the best odds; older men who had been on ADT for years were the least likely to recover.²¹ This has practical implications: the side effects of ADT, including fatigue, body composition changes, and sexual dysfunction, may persist well after treatment ends.

How Exercise Counteracts ADT Side Effects

If there is one intervention with broad evidence for helping men on ADT, it is structured exercise. A year-long randomized trial found that resistance training reduced fatigue and increased vitality in men receiving ADT, with those who started with the worst fatigue gaining the most.²² A systematic review and meta-analysis of supervised exercise programs found moderate-certainty evidence that exercise improved muscle strength and cardiovascular fitness compared to no exercise, with the improvement in peak oxygen uptake estimated at about 8%.²³

Exercise does not fully reverse the effects of testosterone loss, but it can slow the decline in muscle mass, partially counteract fat gain, improve heart health markers, and ease the fatigue that many men describe as ADT’s most debilitating side effect. Most guidelines now recommend that men on ADT engage in a combination of resistance and aerobic exercise, ideally supervised, starting as early as possible in treatment rather than waiting until symptoms become severe.

Monitoring While on ADT

Once you start ADT, your medical team will track your PSA levels to gauge whether the cancer is responding. But monitoring testosterone itself is equally important. Routine testosterone measurement throughout treatment helps confirm that the drug is actually suppressing levels adequately.²⁴ Some men on injectable GnRH drugs experience incomplete suppression or intermittent “breakthroughs” where testosterone rises between doses.

There has been debate about whether driving testosterone below the traditional castrate threshold offers additional benefit. One study found that men who reached very low levels within the first month of ADT had a longer time before their cancer became resistant.²⁵ However, a phase III trial analyzing radiotherapy patients found no statistically significant difference in cancer outcomes between those whose testosterone dropped very low versus those who stayed in the standard castrate range.²⁶ The clinical relevance of ultra-low testosterone targets remains unsettled, but ensuring that testosterone stays consistently below the castrate threshold is something every man on ADT should verify with his care team.

When ADT Stops Working

Most prostate cancers eventually find ways to grow despite castrate levels of testosterone. This stage, called castration-resistant prostate cancer, does not mean hormonal treatment is irrelevant. It means the cancer has adapted. The androgen receptor remains a primary driver of resistance. Tumors can amplify the receptor so that even trace amounts of androgen activate it, develop mutations that let the receptor respond to non-androgen signals, or produce their own androgens internally.²⁷ Residual hormones within cancer cells, maintained by metabolic pathways that continue to function despite castration, also play a role.²⁸

Understanding this matters because ADT is not stopped when a cancer becomes castration-resistant. Instead, treatments are layered on top of it. Drugs like enzalutamide and abiraterone were specifically designed to target the mechanisms of castration resistance, blocking either the receptor more thoroughly or the tumor’s ability to make its own androgens. Chemotherapy, targeted radiation, and immunotherapy are other tools used at this stage, but all are typically combined with continued baseline testosterone suppression.

Bipolar Androgen Therapy

One of the more counterintuitive ideas in prostate cancer research involves deliberately giving testosterone to men whose cancer has become resistant to ADT. Bipolar androgen therapy cycles between very low and very high testosterone levels, with injections of supraphysiological testosterone given periodically while maintaining underlying castration. The rationale is that cancer cells adapted to near-zero testosterone may be vulnerable to sudden high doses, which can destabilize DNA repair mechanisms and the androgen receptor signaling the tumors depend on.²⁹

Early-phase trials have shown that this approach can induce tumor responses in a subset of men with castration-resistant disease, and researchers are now testing it in combination with other agents like the DNA-repair inhibitor olaparib.³⁰ Beyond potential tumor control, men on bipolar androgen therapy often report improvements in energy, mood, and sexual function during the high-testosterone phase, giving them periodic relief from ADT’s quality-of-life toll. The approach is still experimental, but it represents a genuine rethinking of how androgen manipulation can be used against a disease that was once treated solely by hormone deprivation.